<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30290608</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>23</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>23</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1536-5964</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>97</Volume>                    <Issue>40</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                    </PubDate>                </JournalIssue>                <Title>Medicine</Title>                <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>            </Journal>            <ArticleTitle>Everolimus-induced pulmonary toxicity: Findings on 18F-FDG PET/CT imaging.</ArticleTitle>            <Pagination>                <MedlinePgn>e12518</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000012518</ELocationID>            <Abstract>                <AbstractText>The everolimus-exemestane combination is indicated in advanced breast cancer treatment and usually well tolerated. The objective of the study was to determine the frequency of everolimus lung side effects and investigate their imaging characteristics on positron emission tomography with 18F-fluoro-deoxy-glucose combined with computerized tomography (F-FDG PET/CT).Our single-center retrospective descriptive study systematically included all patients with metastatic breast cancer treated by this combination (n = 29 representing 57 F-FDG PET/CT). Number of segments involved was quantified. Maximum standardized uptake value (SUVmax), average standardized uptake value (SUVmean), metabolic target volume (MTV), and total lesion glycolysis (TLG) were measured. Severe pneumopathy was studied by subgroup analysis.Pleuroparenchymal anomalies rate detected on F-FDG PET/CT was 62%. Alveolar-interstitial lesions were mainly observed (89%) and affected 2.8 segments (0.5-11.5) with a median of 2 segments. S7 and S10 were the most involved segments with SUVmax 3.9 (1.3-8.8) and SUVmean 2.2 (0.7-4.9). Statistically significant difference (P = .02) was found with number of segment involved to characterize severe pneumopathy (average of 6.3 segments [2.5-11.5] vs 1.9 segments [0.5-8] for interstitial lung disease) but not with SUVmax, SUVmean, MTV, TLG (P = .14, 0.22, 0.22, and 0.17, respectively).The F-FDG PET/CT could highlight pulmonary everolimus side effects, with a typical imaging pattern: alveolar-interstitial opacities associated with moderate uptake, more or less extensive, mainly affecting the lower lobes. Rarely, a pseudotumoral aspect may be detected, corresponding to a pitfall. MTV or TLG showed a tendency to differentiate severe pneumopathy vs interstitial lung disease but no statistically significant differences was observed contrarily to the number of segments involved. Further studies are necessary to determine if the F-FDG PET/CT could early predict adverse effects of mTOR inhibitors.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Dejust</LastName>                    <ForeName>Sebastien</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nuclear Medicine, Jean Godinot Institut.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Morland</LastName>                    <ForeName>David</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nuclear Medicine, Jean Godinot Institut.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Laboratory of Biophysics, University of Reims.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bruna-Muraille</LastName>                    <ForeName>Claire</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nuclear Medicine, Jean Godinot Institut.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Eymard</LastName>                    <ForeName>Jean-Christophe</ForeName>                    <Initials>JC</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Jean Godinot Institut.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yazbek</LastName>                    <ForeName>Gabriel</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Jean Godinot Institut.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Savoye</LastName>                    <ForeName>Aude-Marie</ForeName>                    <Initials>AM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Jean Godinot Institut.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Papathanassiou</LastName>                    <ForeName>Dimitri</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nuclear Medicine, Jean Godinot Institut.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Laboratory of Biophysics, University of Reims.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Research Center in Information and Communication Sciences and Technologies, EA 3804, University of Reims, Reims, France.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D064888">Observational Study</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Medicine (Baltimore)</MedlineTA>            <NlmUniqueID>2985248R</NlmUniqueID>            <ISSNLinking>0025-7974</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000730">Androstadienes</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0Z5B2CJX4D</RegistryNumber>                <NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>9HW64Q8G6G</RegistryNumber>                <NameOfSubstance UI="D000068338">Everolimus</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.1.1</RegistryNumber>                <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>NY22HMQ4BX</RegistryNumber>                <NameOfSubstance UI="C056516">exemestane</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>AIM</CitationSubset>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000730" MajorTopicYN="N">Androstadienes</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000068338" MajorTopicYN="N">Everolimus</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006019" MajorTopicYN="N">Glycolysis</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017563" MajorTopicYN="N">Lung Diseases, Interstitial</DescriptorName>                <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>                <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000072078" MajorTopicYN="N">Positron Emission Tomography Computed Tomography</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D047368" MajorTopicYN="N">Tumor Burden</DescriptorName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>7</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>7</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30290608</ArticleId>            <ArticleId IdType="doi">10.1097/MD.0000000000012518</ArticleId>            <ArticleId IdType="pii">00005792-201810050-00022</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>